1693758-51-8

Basic information

• Product Name: IPI-549
• Synonyms: IPI-549;(S)-2-amino-N-(1-(8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;IPI-549(IPI549);IPI-549, 98%, a potent and selective PI3Kγ Inhibitor
• CAS NO: 1693758-51-8
• Molecular Formula: C30H24N8O2
• Molecular Weight: 528.56
• EINECS: -0
• Product Categories: API
• Mol File: 1693758-51-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to at least 25 mg/ml)
• PKA: 10.81±0.46(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
• CAS DataBase Reference: IPI-549(CAS DataBase Reference)
• NIST Chemistry Reference: IPI-549(1693758-51-8)
• EPA Substance Registry System: IPI-549(1693758-51-8)

Safety Data

• Hazardous Substances Data: 1693758-51-8(Hazardous Substances Data)

Usage

Description

IPI-549 (1693758-51-8) is a potent and highly selective inhibitor of PI3K-γ in both biochemical (IC50?= 16 nM) and cellular (IC50?= 12.2 nM) assays.1?Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression.2?IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3K-γ inhibition via IPI-549.3?IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines.3?IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance.4

Uses

IPI-549 is a selective phosphoinositide-3-kinase (PI3Kγ) Inhibitor. PI3Kγ inhibitors can be used to develop potential treatment for inflammatory and autoimmune diseases.

References

1) Evans?et al.?(2016)?Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-gamma Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate; ACS Med. Chem. Lett.?7?862 2) Kaneda?et al.?(2016)?PI3Kγ is a molecular switch that controls immune suppression; Nature?539?437 3) De Henau?et al.?(2016);?Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells; Nature?539?443 4) De Vera?et al. (2019);?Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo; Cancer Letters?442?91

Upstream product

• 1260169-02-5 2-aminopyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 
• 1201657-09-1 1-methyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole 
• 1383056-73-2 2-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid 
• 1350643-72-9 (S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinoline-1(2H)-one 
• 1394003-86-1 2-aminopyrazolo[1,5-a]pyrimidine-3-carboxylic acid 
• 39806-89-8 4-ethynyl-1-methyl-1-H-pyrazole 
• 1466563-96-1 C₂₉H₂₇ClN₆O₄ 
• 1386861-46-6 2-chloro-6-methyl-N-phenylbenzamide 
• 62-53-3 aniline 
• 21327-86-6 2-chloro-6-methylbenzoic acid 
• 1466563-97-2 C₂₄H₁₉ClN₆O₂ 

Relevant articles and documents

SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.